Medtronic has announced U.S. Food and Drug Administration approval for its BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) technologies. These advancements enhance the Percept DBS neurostimulators, allowing real-time therapy adjustments based on a patient’s brain activity. Unlike traditional deep brain stimulation (DBS), which provides continuous stimulation, aDBS automatically adapts therapy to manage motor symptoms more effectively. The BrainSense Electrode Identifier improves efficiency by reducing the time required for clinicians to program DBS settings, offering a more precise and tailored approach to treatment. While there's no cure for neurological conditions like Parkinson's, deep brain stimulation (DBS) has been improving lives for over 30 years. Similar to a pacemaker for the brain, DBS uses a surgically implanted device to deliver electrical signals to brain areas affected by neurological disorders.
Medtronic developed BrainSense technology over a decade, leveraging brain-computer interface (BCI) capabilities to detect and classify brain signals. The ADAPT-PD clinical trial, conducted at institutions including Stanford University, Massachusetts General Hospital, and the University of California San Francisco, evaluated the safety and effectiveness of aDBS compared to continuous DBS. Researchers found that aDBS may improve symptom control for patients experiencing fluctuations and side effects from traditional therapy. Medtronic has served more than 185,000 patients with movement disorders worldwide and continues to develop advanced neuromodulation treatments to enhance patient care.
